Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (10): 1161-1167.doi: 10.12092/j.issn.1009-2501.2023.10.010

Previous Articles     Next Articles

Trimethylamine N-oxide: the potential target for osteoporosis treatment

ZHAO Yangting1,2, CHEN Chongyang1,2, PAN Binjing1,2, LV Xiaoyu1,2, LIU Jingfang1,2   

  1. 1The First Clinical Medical College, Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Endocrinology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2023-04-18 Revised:2023-06-01 Online:2023-10-26 Published:2023-10-26

Abstract: Trimethylamine N-oxide (TMAO) is an intestinal flora metabolite produced in the liver by the oxidation of trimethylamine (TMA) by hepatic enzymes. Recently, it has been found that plasma TMAO levels play an important role in the development and progression of osteoporosis. This review has presented the physiological functions and metabolic processes of TMAO, and its effects on the development and progression of osteoporosis through oxidative stress and inflammation. Plasma TMAO levels are influenced by diet as well as medications, which provides a new perspective and target for the treatment and prevention of osteoporosis.

Key words: trimethylamine N-oxide, intestinal flora, osteoporosis, bone mineral density, fracture

CLC Number: